Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis

Peritoneal Dialysis International

Volumn 20, Issue 2, 2000, Pages 232-234

  Li, Philip Kam Tao ^a   Ip, Margaret ^a   Law, Man Ching ^a   Szeto, Cheuk Chun ^a   Leung, Chi Bon ^a   Wong, Teresa Y H ^a   Ho, Kelvin K L ^a   Wang, Angela Y M ^a   Lui, Siu Fai ^a   Yu, Alex W Y ^a   Lyon, Donald J ^a   Cheng, Augustine F B ^a   Lai, Kar Neng ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEPHALOSPORIN DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DECISION TREE; FEMALE; HUMAN; INFUSION; MALE; MICROBIOLOGY; MIDDLE AGED; PERITONITIS;

CEPHALOSPORINS; DECISION TREES; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS;

EID: 0034150615     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002000212     Document Type: Article

References (11)

1. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA, et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996; 16:557-73.
2. Barradell LB and Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 47:471-505.
3. Vas SI. Peritonitis during CAPD. A mixed bag. Perit Dial Bull 1981; 1:47-9.
4. Waterworth PM. Quantitative methods for bacterial sensitivity testing. In: Reeves DS, Phillips I, Williams JD, Wise R, eds. Laboratory methods in antimicrobial chemotherapy. Edinburgh: Churchill Livingstone, 1978:137-43.
5. British Society for Antimicrobial Chemotherapy. Diagnosis and management of peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1987; 1:845-9.
6. Troidle L, Kliger AS, Gorban-Brennan N, Fikrig M, Golden M, Finkelstein FO. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996; 50:1368-72.
7. Aminoglycoside Resistance Study Groups. The most frequent aminoglycoside resistance mechanisms - changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin Infect Dis 1997; 24(Suppl 1):S46-62.
8. Gendeh BS, Said H, Gibb AG, Aziz NS, Kong N, Zahir ZM. Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis. J Laryngol Otol 1993; 107:681-5.
9. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999; 34:14-20.
10. Gucek A, Bren AF, Hergouth V, Lindic J. Cefazolin and netilmicin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1997; 13:218-20.
11. Lai MN, Kao MT, Chen CC, Cheung SY, Chung WK. Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis. Perit Dial Int 1997; 17:87-9.